Two ways to take it without a needle
A dissolvable melt and an oral solution sit beside two injectable programmes, all four priced on the same page. An oral solution is a form we have not recorded on another row here, though nothing in this roster's data distinguishes a solution from any other oral preparation, so read that as a gap in our record rather than a census.
Everything is sold either as a single purchase or on a subscription, with both figures printed together. Showing the two side by side is the honest way to advertise a subscription discount.
It says four weeks, then calls it monthly
Every card carries the same phrase beside its price: every four weeks. That is the disclosure most sellers here omit, and it is here on all four products.
Two of those products are named as monthly programmes. So the same card calls the cycle four weeks and the product monthly, which are thirteen charges a year and twelve.
We store every figure as a non-monthly rate for that reason. The seller supplies both halves of the contradiction; a reader who trusts the product name will be billed once more a year than they budgeted for.
It never says what the drug is
Each product is labelled by drug class — a GLP-1, or a GIP and GLP-1 combination — and never by molecule. Semaglutide and tirzepatide appear on the page only inside a general FAQ answer explaining what GLP-1 medicines are.
So we file every figure under an unspecified GLP-1. Two of the four are also priced as a range, with the variant chosen on a later page and the top of the range nearly double the bottom.
The address the letter names is not the address you visit
The FDA's warning letter to this company names a different domain, and that domain now redirects here. The company, the trading name and the letter all connect, but the address on the letter is not the address a reader will use.
The privacy policy names the operating company, a street address and a telephone number, and states it owns the site, so the chain is verifiable.
The GLP-1 lane sits inside a catalogue otherwise dominated by sexual-health products. No compounding pharmacy is named, no prescribing clinician is named, and no state list appears.
It carries an FDA warning letter issued in February 2026 over false and misleading claims and misbranding. That is a disclosure and it does not move this seller's position here.
Peak Now's published pricing
| Medication | Price | Verified |
|---|---|---|
| Glp-1 (compounded-oral) | $224.99⛔ BILLED EVERY FOUR WEEKS, NOT MONTHLY, IN THE SELLER'S OWN WORDS: the shop card reads "GLP-1 Dissolvable Melts $249.99 — or $224.99 every 4 weeks". The lower figure is the subscription rate and the higher one the single purchase; thirteen four-week cycles fall in a year. ⛔ The product names no molecule; semaglutide and tirzepatide appear on this page only inside a general FAQ answer about the drug class | September 2026source |
| Glp-1 (compounded-oral) | $224.99⛔ THE SAME FOUR-WEEK CYCLE: "GLP-1 Oral Solution ... $249.99 — or $224.99 every 4 weeks". Same unnamed molecule as the melts, and the same figure | September 2026source |
| Glp-1 (compounded) | $170.99⛔⛔ THE PRODUCT IS CALLED "GLP-1 Monthly Weight Loss Program" AND IS BILLED "every 4 weeks" — the seller's own product name contradicts its own billing cycle on the same card. The card prints a range, $189.99 to $299.99 as a single purchase or $170.99 to $269.99 every four weeks, with the variants chosen on the product page; the bottom of the subscription range is recorded | September 2026source |
| Glp-1 (compounded) | $242.99⛔ THE SAME CONTRADICTION AND THE SAME CYCLE: "GIP and GLP-1 Monthly Weight Loss Program ... $269.99 – $399.99 — or from $242.99 – $359.99 every 4 weeks". The bottom of the subscription range is recorded; the molecule is not named | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 264 providers reviewed here are paid partners today; the other 260 are not. See how this works.
See Peak Now's current price →Good fit if
- Readers who want to swallow rather than inject and want the option priced in public.
- Buyers who want the billing cycle stated on the card rather than inferred.
- People who want the choice between buying once and subscribing, with both figures visible.
Look elsewhere if
- Anyone who needs to know which molecule they are taking.
- Buyers who will budget by the product name rather than the billing cycle.
- Readers who need a single figure rather than a range.
- People who need a named pharmacy, prescriber or state list.
How this review was verified
- Read the homepage, the privacy policy, the shop index and the weight-loss catalogue on 7 September 2026, comparing requested to effective URLs, with a nonsense path on the same host in the same run — it returned a 404 with a body larger than several real pages, so the status code decided.
- Requested the domain named in the FDA letter and recorded that it redirects cross-host to this one.
- Took every figure from the catalogue card that carries it, with its billing phrase and both its single-purchase and subscription rates.
- Searched the catalogue page for a molecule name and found the two drug names only inside a general FAQ answer, never against a price, so no figure is filed under a named drug.
- Screened the live FDA warning-letter datatable by entity name with a positive control returning exactly one row and a nonsense control returning none.